131 related articles for article (PubMed ID: 2718607)
21. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
[TBL] [Abstract][Full Text] [Related]
22. Immunization with a vaccinia recombinant expressing the F protein protects rabbits from challenge with a lethal dose of rinderpest virus.
Barrett T; Belsham GJ; Subbarao SM; Evans SA
Virology; 1989 May; 170(1):11-8. PubMed ID: 2718375
[TBL] [Abstract][Full Text] [Related]
23. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.
Legrand FA; Verardi PH; Jones LA; Chan KS; Peng Y; Yilma TD
J Virol; 2004 Mar; 78(6):2770-9. PubMed ID: 14990697
[TBL] [Abstract][Full Text] [Related]
24. Identification of vaccinia promoters by heterologous expression of hepatitis B surface antigen in mouse cells infected by recombinant vaccinia viruses.
Barbeyron T; Mars M; Schroeder E; Malpièce Y; Plucienniczak A; Beaud G; Streeck RE
Biochim Biophys Acta; 1987 Dec; 910(3):240-4. PubMed ID: 3676323
[TBL] [Abstract][Full Text] [Related]
25. A recombinant vaccinia virus expressing hepatitis B virus middle surface protein. Restricted expression of HBV antigens in human diploid cells.
Kutinová L; Nĕmecková S; Hamsíková E; Press M; Závadová H; Hirsch I; Nĕmecek V; Krchnák V; Smrt J; Slonim D
Arch Virol; 1990; 112(3-4):181-93. PubMed ID: 2378567
[TBL] [Abstract][Full Text] [Related]
26. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
[TBL] [Abstract][Full Text] [Related]
27. A new genetically engineered vaccine for animal growth promotion.
Xu WZ; Du NX; Li GD; Wang Y; Li ZP
Sci China B; 1994 Oct; 37(10):1234-41. PubMed ID: 7865123
[TBL] [Abstract][Full Text] [Related]
28. [Construction of recombinant vaccinia virus expressing HSV-2 gD gene as live recombinant vaccine strain].
Yan H; Rong M; Ruan L; Hou Y; He N; Zhu J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Mar; 11(1):16-20. PubMed ID: 15619895
[TBL] [Abstract][Full Text] [Related]
29. Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines.
NAM JH; BANG HS; CHO HW; CHUNG YH
Acta Virol; 2007; 51(2):125-30. PubMed ID: 17900219
[TBL] [Abstract][Full Text] [Related]
30. [Vaccination with three HIV-1 cross neutralizing epitopes fused to HBV S antigen could induce robust antibody immune response in mice].
Li XR; Chen H; Wang W; Deng Y; Qi XR; Gao YY; Meng X; Tan WJ; Ruan L
Bing Du Xue Bao; 2008 Jul; 24(4):260-7. PubMed ID: 18780627
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of antibody formation to the vaccinia virus in human subjects and rabbits in response to the administration of a recombinant vaccinia-hepatitis B vaccine].
Cheliapov NV; Chernos VI; Andzhaparidze OG
Vopr Virusol; 1988; 33(2):175-9. PubMed ID: 2842961
[TBL] [Abstract][Full Text] [Related]
32. Construction of recombinant vaccinia virus expressing Rinderpest Virus nucleocapsid protein and its immunogenicity in mice.
Ohishi K; Kamata H; Ohkubo S; Yamanouchi K; Kai C
J Vet Med Sci; 1998 May; 60(5):655-6. PubMed ID: 9637306
[TBL] [Abstract][Full Text] [Related]
33. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene.
Shida H; Hinuma Y; Hatanaka M; Morita M; Kidokoro M; Suzuki K; Maruyama T; Takahashi-Nishimaki F; Sugimoto M; Kitamura R
J Virol; 1988 Dec; 62(12):4474-80. PubMed ID: 3184271
[TBL] [Abstract][Full Text] [Related]
34. Vaccinia virus recombinants co-expressing hepatitis B virus surface and core antigens.
Kunke D; Broucek J; Kutinová L; Nĕmecková S; Ludvíková V; Strnad I; Kramosil J; Nemcová J; Schramlová J; Simonová V
Virology; 1993 Jul; 195(1):132-9. PubMed ID: 8317089
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
[TBL] [Abstract][Full Text] [Related]
36. A recombinant vaccinia virus expressing hepatitis A virus structural polypeptides: characterization and demonstration of protective immunogenicity.
Karayiannis P; O'Rourke S; McGarvey MJ; Luther S; Waters J; Goldin R; Thomas HC
J Gen Virol; 1991 Sep; 72 ( Pt 9)():2167-72. PubMed ID: 1654376
[TBL] [Abstract][Full Text] [Related]
37. Live recombinant vaccines using genetically engineered vaccinia virus.
Paoletti E; Perkus ME; Piccini A
Antiviral Res; 1985; Suppl 1():301-7. PubMed ID: 3866514
[No Abstract] [Full Text] [Related]
38. Two vaccinia virus recombinants expressing HBsAg with different concentration of A- and pre-S2 antigenic determinants.
Chelyapov NV; Rakhilina LE; Antonova TP; Chernos VI; Grigorjev VG; Chudakova EA; Pashvykina GV; Zakharova LG; Altstein AD; Kutinová L
Acta Virol; 1991 Sep; 35(5):413-22. PubMed ID: 1726675
[TBL] [Abstract][Full Text] [Related]
39. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein.
Dallo S; Maa JS; Rodriguez JR; Rodriguez D; Esteban M
Virology; 1989 Nov; 173(1):323-9. PubMed ID: 2510402
[TBL] [Abstract][Full Text] [Related]
40. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.
Smith KA; Stallard V; Roos JM; Hart C; Cormier N; Cohen LK; Roberts BE; Payne LG
Vaccine; 1993; 11(1):43-53. PubMed ID: 8427036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
